Clinical Trial Update: S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib for unresectable or metastatic gallbladder cancer and cholangiocarcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer

Drugs mentioned

• Nexavar (sorafenib) (sorafenib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder | Phase 2 | Status: COMPLETED